Latest Articles

Publication Date
Endometrium-targeted mRNA-lipid nanoparticles for treating reproductive conditions - Nature

Endometrium-targeted mRNA-lipid nanoparticles for treating reproductive conditions Nature

Published: Feb. 26, 2026, 10:22 a.m.
An Overview of Endometriosis and Potential Pharmacogenetic Targets.

Endometriosis is a chronic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. It affects approximately 10-15% of women of reproductive age globally and is characterized …

Published: Feb. 25, 2026, midnight
Systems-level actions of luteolin in female reproductive disorders: from molecular mechanisms to clinical translation.

Female reproductive disorders represent a major global health challenge. Despite their clinical heterogeneity, these conditions share core pathological mechanisms including oxidative stress, chronic inflammation, hormonal imbalance, metabolic dysfunction, extracellular matrix …

Published: Feb. 25, 2026, midnight
A biopsychosocial perspective on endometriosis: the importance of psychological inflexibility.

Treatment strategies for endometriosis have traditionally been biomedical. There is a need for a more multidimensional understanding of endometriosis and more targeted and individualized treatment interventions, including psychological approaches.

Published: Feb. 24, 2026, midnight
Early Detection and Screening in Endometriosis.

Endometriosis affects 1 in 10 women of reproductive age and is often diagnosed after years of symptom onset. Although population-wide screening is not recommended in asymptomatic women, targeted imaging-based assessment …

Published: Feb. 24, 2026, midnight
Identification of a Potential Biomarker PDGFRA for Endometriosis Based on Comprehensive Analysis of Multiple Omics Data.

Endometriosis (EMs) is a common chronic inflammatory gynecological disorder. But the exact pathogenetic mechanism of the disease is not clear, with some theories proposing that the disease is caused by …

Published: Feb. 20, 2026, midnight
Gaudium IVF and Women Health ipo date, Share Price Target Tomorrow, 2026, 2027, 2030 - shareprice-target.com

Gaudium IVF and Women Health ipo date, Share Price Target Tomorrow, 2026, 2027, 2030 shareprice-target.com

Published: Feb. 19, 2026, 8:30 a.m.
Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair.

Endometriosis is a chronic, hormone-dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is effective for pain relief, …

Published: Feb. 18, 2026, midnight
The letrozole use in reproductive medicine: Beyond aromatase inhibition - a comprehensive review.

Letrozole and other aromatase inhibitors are increasingly recognized as first-line ovulation induction (OI) medications, offering an efficient and physiologic approach to ovarian stimulation that enhances outcomes in reproductive medicine. By …

Published: Feb. 17, 2026, midnight
Soluble Mediators Related to Immunity in Pregnancy-Related Disorders: Roles of Immune Checkpoints, Platelet Activation Markers, TNF Receptors, and NETs.

Soluble immune mediators are key regulators of immune responses that help maintain self-tolerance and prevent autoimmunity. Recently, many forms of these mediators have been found, including soluble immune checkpoints, soluble …

Published: Feb. 16, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!